Patients over the age of 65, with heart disease, electrolyte imbalances, and those taking certain medications are at higher risk for QTC prolongation.
Baseline ECGs and electrolyte panels, along with close monitoring, are essential to identify and prevent QTc prolongation in high-risk patients.
Deep dives
Identifying High-Risk Patients for QTC Prolongation
Patients over the age of 65, with heart disease, electrolyte imbalances, and those taking certain medications are at higher risk for QTC prolongation. Certain factors, such as thyroid disease and zeprazidone use, increase the risk further. Vital signs, baseline labs, and medication review can help clinicians identify high-risk patients for closer monitoring and preventive measures.
Managing Patients on QTC Prolonging Psychiatric Medications
Clinicians should obtain a baseline ECG and vital signs before initiating a QTC prolonging medication. Repeat ECGs and electrolyte panels are necessary after the medication reaches steady state, and at least annually thereafter. If the QTC interval reaches 470-500 milliseconds for males or 480-500 milliseconds for females, clinicians should consider substituting the medication with a non-QTC prolonging agent or reducing the dose. Sudden increases in the QTC interval or durations of 500 milliseconds or more require immediate discontinuation of the medication and a cardiology consultation.
Overview of QTC Prolongation Risks for Psychotropic Medications
While most selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have a low risk of QTC prolongation, citalopram at doses exceeding 40 milligrams carries some risk. Tricyclic antidepressants, low-potency first-generation antipsychotics, and ziprasidone have significant QT prolongation potential, while newer antidepressants have limited data available. Lithium, thyrothiasine, some first-generation antipsychotics, and high-dose citalopram carry varying degrees of QT prolongation risk. Stimulants, benzodiazepines, and buspirone generally have little impact on the QT interval. Concurrent use of multiple QT prolonging medications significantly elevates the risk of QT interval prolongation, emphasizing the need for caution and monitoring when prescribing medications with QT prolongation potential.
Several psychiatric medications prolong the QTc interval and place patients at risk of the dreaded torsade de pointes. Some patients are particularly vulnerable to QTc prolongation: the elderly, patients with heart disease and electrolyte imbalances, and patients taking certain medications, like thioridazine and ziprasidone. In this podcast, we provide a step-by-step guide so that you can keep your patients safe from this cardiovascular side effect.
Victoria Hendrick, MD, and Prabhjot Gill, BS, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode